The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.
The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.
A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.